Accelerator Centre Announces Graduation of Expeflow and Rapid Novor from The Accelerator Program
Waterloo (Ontario), CANADA, December 6, 2018 – The Accelerator Centre (AC) is pleased to announce its newest graduates of The Accelerator Program™. The graduation of Expeflow and Rapid Novor marks the 6oth and 61st successful graduation from the AC’s world-renowned program.
“Our mission at the AC is to help technology startups build globally successful, high impact companies,” say CEO, Paul Salvini. “And the evidence shows that we do that exceptionally well. From being ranked among the top accelerators in the world earlier this year to our recognition as the top incubator in Canada by the Digital Finance Institute, the world is taking notice of the work we do here and of the success of the companies that participate in our programming.
The graduation of Expeflow and Rapid Novor is tangible evidence of the talent and potential that is here in Waterloo and a clear demonstration of the kind of passion and dedication required to grow and scale a successful startup. We are incredibly proud to count these two companies as graduates and look forward to continuing to support them through our post graduate program as they scale and see global success.”
For insurers who are looking to better compete, provide effective and efficient insurance and stop leakage related to claims management inefficiencies, EXPEFLOW is a Cloud-based, secure, centrally administered claims management platform for medical and healthcare claims that streamlines processes, increases team collaboration, elevates compliance and provides business intelligence and analytics not previously available.
Rapid Novor Inc is the world’s leader in antibody protein sequencing technology. Specializing in the field of mass spectrometry-based proteomics, the team has developed the technology to directly sequence the antibody proteins without needs to access the cell line.
As a University of Waterloo spin-off, the company is building its technology portfolios based on the twenty years of scientific research and inventions from Dr. Bin Ma, co-founder and chief scientist. The company’s REmAb™ antibody protein sequencing service has allowed the accurate sequencing of any given antibody proteins routinely. The company’s WILD™ service is the first commercially available service that can accurately distinguish the isomeric Isoleucine and Leucine using mass spectrometry.
For further information, please contact:
Marketing and Community Manager